Document:

<PAGE>

                                                                    EXHIBIT 10.1

                                E.PIPHANY, INC.

                        1999 EMPLOYEE STOCK PURCHASE PLAN

                  (Amended and Updated as of October 15, 2002)

      The following constitute the provisions of the 1999 Employee Stock
Purchase Plan of E.piphany, Inc.

      1.    Purpose. The purpose of the Plan is to provide employees of the
Company and its Designated Subsidiaries with an opportunity to purchase Common
Stock of the Company through accumulated payroll deductions. It is the intention
of the Company to have the Plan qualify as an "Employee Stock Purchase Plan"
under Section 423 of the Internal Revenue Code of 1986, as amended. The
provisions of the Plan, accordingly, shall be construed so as to extend and
limit participation in a manner consistent with the requirements of that section
of the Code.

      2.    Definitions.

            (a)   "Board" shall mean the Board of Directors of the Company.

            (b)   "Code" shall mean the Internal Revenue Code of 1986, as
                  amended.

            (c)   "Common Stock" shall mean the common stock of the Company.

            (d)   "Company" shall mean E.piphany, Inc. and any Designated
Subsidiary of the Company.

            (e)   "Compensation" shall mean all base straight time gross
earnings, commissions, overtime, shift premium, and bonuses, but exclusive of
other compensation.

            (f)   "Designated Subsidiary" shall mean any Subsidiary that has
been designated by the Board from time to time in its sole discretion as
eligible to participate in the Plan.

            (g)   "Employee" shall mean any individual who is an Employee of the
Company for tax purposes whose customary employment with the Company is at least
twenty (20) hours per week and more than five (5) months in any calendar year.
For purposes of the Plan, the employment relationship shall be treated as
continuing intact while the individual is on sick leave or other leave of
absence approved by the Company. Where the period of leave exceeds 90 days and
the individual's right to reemployment is not guaranteed either by statute or by
contract, the employment relationship shall be deemed to have terminated on the
91st day of such leave.

            (h)   "Enrollment Date" shall mean the first Trading Day of each
Offering Period.

            (i)   "Exercise Date" shall mean the last Trading Day of each
Purchase Period.

            (j)   "Fair Market Value" shall mean, as of any date, the value of
Common Stock determined as follows:

                                      -1-
<PAGE>

                  (i)   If the Common Stock is listed on any established stock
exchange or a national market system, including without limitation the Nasdaq
National Market or The Nasdaq SmallCap Market of The Nasdaq Stock Market, its
Fair Market Value shall be the closing sales price for such stock (or the
closing bid, if no sales were reported) as quoted on such exchange or system on
the day of determination, as reported in The Wall Street Journal or such other
source as the Board deems reliable;

                  (ii)  If the Common Stock is regularly quoted by a recognized
securities dealer but selling prices are not reported, its Fair Market Value
shall be the mean of the closing bid and asked prices for the Common Stock on
the day of determination, as reported in The Wall Street Journal or such other
source as the Board deems reliable;

                  (iii) In the absence of an established market for the Common
Stock, the Fair Market Value thereof shall be determined in good faith by the
Board; or

                  (iv)  For purposes of the Enrollment Date of the first
Offering Period under the Plan, the Fair Market Value shall be the initial price
to the public as set forth in the final prospectus included within the
registration statement in Form S-1 filed with the Securities and Exchange
Commission for the initial public offering of the Company's Common Stock (the
"Registration Statement").

            (k)   "Offering Periods" shall mean the periods of approximately
twenty-four (24) months during which an option granted pursuant to the Plan may
be exercised, commencing on the first Trading Day on or after May 1 and November
1 of each year and terminating on the last Trading Day in the periods ending
twenty-four months later; provided, however, that the first Offering Period
under the Plan shall commence with the first Trading Day on or after the date on
which the Securities and Exchange Commission declares the Company's Registration
Statement effective and ending on the last Trading Day on or before October 31,
2001, and the second Offering Period under the Plan shall commence on the first
Trading Day on or after May 1, 2000 and terminate on the last Trading Day in the
period ending twenty-four months later. The duration and timing of Offering
Periods may be changed pursuant to Section 4 of this Plan.

            (l)   "Plan" shall mean this 1999 Employee Stock Purchase Plan.

            (m)   "Purchase Period" shall mean the approximately six month
period commencing after one Exercise Date and ending with the next Exercise
Date, except that the first Purchase Period of any Offering Period shall
commence on the Enrollment Date and end with the next Exercise Date.
Notwithstanding the above, the first Purchase Period under the Plan shall
commence on or after the date on which the Securities and Exchange Commission
declares the Company's Registration Statements effective and ending on the last
Trading Day on or before April 30, 2000.

            (n)   "Purchase Price" shall mean 85% of the Fair Market Value of a
share of Common Stock on the Enrollment Date or on the Exercise Date, whichever
is lower; provided however, that the Purchase Price may be adjusted by the Board
pursuant to Section 20.

            (o)   "Reserves" shall mean the number of shares of Common Stock
covered by each option under the Plan which have not yet been exercised and the
number of shares of

                                      -2-
<PAGE>

Common Stock which have been authorized for issuance under the Plan but not yet
placed under option.

            (p)   "Subsidiary" shall mean a corporation, domestic or foreign, of
which not less than 50% of the voting shares are held by the Company or a
Subsidiary, whether or not such corporation now exists or is hereafter organized
or acquired by the Company or a Subsidiary.

            (q)   "Trading Day" shall mean a day on which national stock
exchanges and the Nasdaq System are open for trading.

      3.    Eligibility.

            (a)   Any Employee who shall be employed by the Company on a given
Enrollment Date shall be eligible to participate in the Plan.

            (b)   Any provisions of the Plan to the contrary notwithstanding, no
Employee shall be granted an option under the Plan (i) to the extent that,
immediately after the grant, such Employee (or any other person whose stock
would be attributed to such Employee pursuant to Section 424(d) of the Code)
would own capital stock of the Company and/or hold outstanding options to
purchase such stock possessing five percent (5%) or more of the total combined
voting power or value of all classes of the capital stock of the Company or of
any Subsidiary, or (ii) to the extent that his or her rights to purchase stock
under all employee stock purchase plans of the Company and its subsidiaries
accrues at a rate which exceeds Twenty-Five Thousand Dollars ($25,000) worth of
stock (determined at the fair market value of the shares at the time such option
is granted) for each calendar year in which such option is outstanding at any
time.

      4.    Offering Periods. The Plan shall be implemented by consecutive,
overlapping Offering Periods with a new Offering Period commencing on the first
Trading Day on or after May 1 and November 1 each year, or on such other date as
the Board shall determine, and continuing thereafter until terminated in
accordance with Section 20 hereof; provided, however, that the first Offering
Period under the Plan shall commence with the first Trading Day on or after the
date on which the Securities and Exchange Commission declares the Company's
Registration Statement effective and ending on the last Trading Day on or before
October 31, 2001, and the second Offering Period under the Plan shall commence
on the first Trading Day on or after May 1, 2000 and terminate on the last
Trading Day in the period ending twenty-four months later. The Board shall have
the power to change the duration of Offering Periods (including the commencement
dates thereof) with respect to future offerings without shareholder approval if
such change is announced at least five (5) days prior to the scheduled beginning
of the first Offering Period to be affected thereafter.

      5.    Participation.

            (a)   An eligible Employee may become a participant in the Plan by
completing an Enrollment/Change Form authorizing payroll deductions in the form
of Exhibit A to this Plan and filing it with the Company's Human Resources
Department prior to the applicable Enrollment Date.

            (b)   Payroll deductions for a participant shall commence on the
first payroll following the Enrollment Date and shall end on the last payroll in
the Offering Period to which

                                      -3-
<PAGE>

such authorization is applicable, unless sooner terminated by the participant as
provided in Section 10 hereof.

      6.    Payroll Deductions.

            (a)   At the time a participant files his or her Enrollment/Change
Form, he or she shall elect to have payroll deductions made on each pay day
during the Offering Period in an amount not exceeding 15% of the Compensation
which he or she receives on each pay day during the Offering Period.

            (b)   All payroll deductions made for a participant shall be
credited to his or her account under the Plan and shall be withheld in whole
percentages only. A participant may not make any additional payments into such
account.

            (c)   A participant may discontinue his or her participation in the
Plan as provided in Section 10 hereof, or may increase or decrease the rate of
his or her payroll deductions during the Offering Period by completing or filing
with the Company a new Enrollment/Change Form authorizing a change in payroll
deduction rate. The Board may, in its discretion, limit the number of
participation rate changes during any Offering Period. The change in rate shall
be effective with the first full payroll period following five (5) business days
after the Company's receipt of the new Enrollment/Change Form unless the Company
elects to process a given change in participation more quickly. A participant's
Enrollment/Change Form shall remain in effect for successive Offering Periods
unless terminated as provided in Section 10 hereof.

            (d)   Notwithstanding the foregoing, to the extent necessary to
comply with Section 423(b)(8) of the Code and Section 3(b) hereof, a
participant's payroll deductions may be decreased to zero percent (0%) at any
time during a Purchase Period. Payroll deductions shall recommence at the rate
provided in such participant's Enrollment/Change Form at the beginning of the
first Purchase Period which is scheduled to end in the following calendar year,
unless terminated by the participant as provided in Section 10 hereof.

            (e)   At the time the option is exercised, in whole or in part, or
at the time some or all of the Company's Common Stock issued under the Plan is
disposed of, the participant must make adequate provision for the Company's
federal, state, or other tax withholding obligations, if any, which arise upon
the exercise of the option or the disposition of the Common Stock. At any time,
the Company may, but shall not be obligated to, withhold from the participant's
compensation the amount necessary for the Company to meet applicable withholding
obligations, including any withholding required to make available to the Company
any tax deductions or benefits attributable to sale or early disposition of
Common Stock by the Employee.

      7.    Grant of Option. On the Enrollment Date of each Offering Period,
each eligible Employee participating in such Offering Period shall be granted an
option to purchase on each Exercise Date during such Offering Period (at the
applicable Purchase Price) up to a number of shares of the Company's Common
Stock determined by dividing such Employee's payroll deductions accumulated
prior to such Exercise Date and retained in the Participant's account as of the
Exercise Date by the applicable Purchase Price; provided that in no event shall
an Employee be permitted to purchase during each Purchase Period more than
15,000 shares of the

                                      -4-
<PAGE>

Company's Common Stock (subject to any adjustment pursuant to Section 19), and
provided further that such purchase shall be subject to the limitations set
forth in Sections 3(b) and 12 hereof. The Board may, for future Offering
Periods, increase or decrease, in its absolute discretion, the maximum number of
shares of the Company's Common Stock an Employee may purchase during each
Purchase Period of such Offering Period. Exercise of the option shall occur as
provided in Section 8 hereof, unless the participant has withdrawn pursuant to
Section 10 hereof. The option shall expire on the last day of the Offering
Period.

      8.    Exercise of Option.

            (a)   Unless a participant withdraws from the Plan as provided in
Section 10 hereof, his or her option for the purchase of shares shall be
exercised automatically on the Exercise Date, and the maximum number of full
shares subject to option shall be purchased for such participant at the
applicable Purchase Price with the accumulated payroll deductions in his or her
account. No fractional shares shall be purchased; any payroll deductions
accumulated in a participant's account which are not sufficient to purchase a
full share shall be retained in the participant's account for the subsequent
Purchase Period or Offering Period, subject to earlier withdrawal by the
participant as provided in Section 10 hereof. Any other monies left over in a
participant's account after the Exercise Date shall be returned to the
participant. During a participant's lifetime, a participant's option to purchase
shares hereunder is exercisable only by him or her.

            (b)   If the Board determines that, on a given Exercise Date, the
number of shares with respect to which options are to be exercised may exceed
(i) the number of shares of Common Stock that were available for sale under the
Plan on the Enrollment Date of the applicable Offering Period, or (ii) the
number of shares available for sale under the Plan on such Exercise Date, the
Board may in its sole discretion (x) provide that the Company shall make a pro
rata allocation of the shares of Common Stock available for purchase on such
Enrollment Date or Exercise Date, as applicable, in as uniform a manner as shall
be practicable and as it shall determine in its sole discretion to be equitable
among all participants exercising options to purchase Common Stock on such
Exercise Date, and continue all Offering Periods then in effect, or (y) provide
that the Company shall make a pro rata allocation of the shares available for
purchase on such Enrollment Date or Exercise Date, as applicable, in as uniform
a manner as shall be practicable and as it shall determine in its sole
discretion to be equitable among all participants exercising options to purchase
Common Stock on such Exercise Date, and terminate any or all Offering Periods
then in effect pursuant to Section 20 hereof. The Company may make pro rata
allocation of the shares available on the Enrollment Date of any applicable
Offering Period pursuant to the preceding sentence, notwithstanding any
authorization of additional shares for issuance under the Plan by the Company's
shareholders subsequent to such Enrollment Date.

      9.    Delivery. As promptly as practicable after each Exercise Date on
which a purchase of shares occurs, the Company shall arrange the delivery to
each participant, as appropriate, of the shares purchased upon exercise of his
or her option.

      10.   Withdrawal.

            (a)   A participant may withdraw all but not less than all the
payroll deductions credited to his or her account and not yet used to exercise
his or her option under the Plan at any

                                      -5-
<PAGE>

time by giving written notice to the Company in the form of Exhibit A to this
Plan. All of the participant's payroll deductions credited to his or her account
shall be paid to such participant promptly after receipt of notice of withdrawal
and such participant's option for the Offering Period shall be automatically
terminated, and no further payroll deductions for the purchase of shares shall
be made for such Offering Period. If a participant withdraws from an Offering
Period, payroll deductions shall not resume at the beginning of the succeeding
Offering Period unless the participant delivers to the Company a new
Enrollment/Change Form.

            (b)   A participant's withdrawal from an Offering Period shall not
have any effect upon his or her eligibility to participate in any similar plan
which may hereafter be adopted by the Company or in succeeding Offering Periods
which commence after the termination of the Offering Period from which the
participant withdraws.

      11.   Termination of Employment.

            Upon a participant's ceasing to be an Employee, for any reason, he
or she shall be deemed to have elected to withdraw from the Plan and the payroll
deductions credited to such participant's account during the Offering Period but
not yet used to exercise the option shall be returned to such participant or, in
the case of his or her death, to the person or persons entitled thereto under
Section 15 hereof, and such participant's option shall be automatically
terminated. The preceding sentence notwithstanding, a participant who receives
payment in lieu of notice of termination of employment shall be treated as
continuing to be an Employee for the participant's customary number of hours per
week of employment during the period in which the participant is subject to such
payment in lieu of notice.

      12.   Interest. No interest shall accrue on the payroll deductions of a
participant in the Plan.

      13.   Stock.

            (a)   Subject to adjustment upon changes in capitalization of the
Company as provided in Section 19 hereof, the maximum number of shares of the
Company's Common Stock which shall be made available for sale under the Plan
shall be 3,000,000 shares, plus an annual increase to be added on the first day
of the Company's fiscal year beginning in 2000 equal to the lesser of (i)
3,000,000 shares, (ii) 4% of the outstanding shares on such date or (iii) a
lesser amount determined by the Board.

            (b)   The participant shall have no interest or voting right in
shares covered by his option until such option has been exercised.

            (c)   Shares to be delivered to a participant under the Plan shall
be registered in the name of the participant or in the name of the participant
and his or her spouse.

      14.   Administration. The Plan shall be administered by the Board or a
committee of members of the Board appointed by the Board. The Board or its
committee shall have full and exclusive discretionary authority to construe,
interpret and apply the terms of the Plan, to determine eligibility and to
adjudicate all disputed claims filed under the Plan. Every finding, decision and
determination made by the Board or its committee shall, to the full extent
permitted by law, be final and binding upon all parties.

                                      -6-
<PAGE>

      15.   Designation of Beneficiary.

            (a)   A participant may file a written designation of a beneficiary
who is to receive any shares and cash, if any, from the participant's account
under the Plan in the event of such participant's death subsequent to an
Exercise Date on which the option is exercised but prior to delivery to such
participant of such shares and cash. In addition, a participant may file a
written designation of a beneficiary who is to receive any cash from the
participant's account under the Plan in the event of such participant's death
prior to exercise of the option. If a participant is married and the designated
beneficiary is not the spouse, spousal consent shall be required for such
designation to be effective.

            (b)   Such designation of beneficiary may be changed by the
participant at any time by written notice. In the event of the death of a
participant and in the absence of a beneficiary validly designated under the
Plan who is living at the time of such participant's death, the Company shall
deliver such shares and/or cash to the executor or administrator of the estate
of the participant, or if no such executor or administrator has been appointed
(to the knowledge of the Company), the Company, in its discretion, may deliver
such shares and/or cash to the spouse or to any one or more dependents or
relatives of the participant, or if no spouse, dependent or relative is known to
the Company, then to such other person as the Company may designate.

      16.   Transferability. Neither payroll deductions credited to a
participant's account nor any rights with regard to the exercise of an option or
to receive shares under the Plan may be assigned, transferred, pledged or
otherwise disposed of in any way (other than by will, the laws of descent and
distribution or as provided in Section 15 hereof) by the participant. Any such
attempt at assignment, transfer, pledge or other disposition shall be without
effect, except that the Company may treat such act as an election to withdraw
funds from an Offering Period in accordance with Section 10 hereof.

      17.   Use of Funds. All payroll deductions received or held by the Company
under the Plan may be used by the Company for any corporate purpose, and the
Company shall not be obligated to segregate such payroll deductions.

      18.   Reports. Individual accounts shall be maintained for each
participant in the Plan. Statements of account shall be given to participating
Employees at least annually, which statements shall set forth the amounts of
payroll deductions, the Purchase Price, the number of shares purchased and the
remaining cash balance, if any.

      19.   Adjustments Upon Changes in Capitalization, Dissolution,
Liquidation, Merger or Asset Sale.

            (a)   Changes in Capitalization. Subject to any required action by
the shareholders of the Company, the Reserves, the maximum number of shares each
participant may purchase each Purchase Period (pursuant to Section 7), as well
as the price per share and the number of shares of Common Stock covered by each
option under the Plan which has not yet been exercised shall be proportionately
adjusted for any increase or decrease in the number of issued shares of Common
Stock resulting from a stock split, reverse stock split, stock dividend,
combination or reclassification of the Common Stock, or any other increase or
decrease in the number of shares of Common Stock effected without receipt of
consideration by the Company;

                                      -7-
<PAGE>

provided, however, that conversion of any convertible securities of the Company
shall not be deemed to have been "effected without receipt of consideration."
Such adjustment shall be made by the Board, whose determination in that respect
shall be final, binding and conclusive. Except as expressly provided herein, no
issuance by the Company of shares of stock of any class, or securities
convertible into shares of stock of any class, shall affect, and no adjustment
by reason thereof shall be made with respect to, the number or price of shares
of Common Stock subject to an option.

            (b)   Dissolution or Liquidation. In the event of the proposed
dissolution or liquidation of the Company, the Offering Period then in progress
shall be shortened by setting a new Exercise Date (the "New Exercise Date"), and
shall terminate immediately prior to the consummation of such proposed
dissolution or liquidation, unless provided otherwise by the Board. The New
Exercise Date shall be before the date of the Company's proposed dissolution or
liquidation. The Board shall notify each participant in writing, at least ten
(10) business days prior to the New Exercise Date, that the Exercise Date for
the participant's option has been changed to the New Exercise Date and that the
participant's option shall be exercised automatically on the New Exercise Date,
unless prior to such date the participant has withdrawn from the Offering Period
as provided in Section 10 hereof.

            (c)   Merger or Asset Sale. In the event of a proposed sale of all
or substantially all of the assets of the Company, or the merger of the Company
with or into another corporation, each outstanding option shall be assumed or an
equivalent option substituted by the successor corporation or a Parent or
Subsidiary of the successor corporation. In the event that the successor
corporation refuses to assume or substitute for the option, any Purchase Periods
then in progress shall be shortened by setting a new Exercise Date (the "New
Exercise Date") and any Offering Periods then in progress shall end on the New
Exercise Date. The New Exercise Date shall be before the date of the Company's
proposed sale or merger. The Board shall notify each participant in writing, at
least ten (10) business days prior to the New Exercise Date, that the Exercise
Date for the participant's option has been changed to the New Exercise Date and
that the participant's option shall be exercised automatically on the New
Exercise Date, unless prior to such date the participant has withdrawn from the
Offering Period as provided in Section 10 hereof.

      20.   Amendment or Termination.

            (a)   The Board of Directors of the Company may at any time and for
any reason terminate or amend the Plan. Except as provided in Section 19 hereof,
no such termination can affect options previously granted, provided that an
Offering Period may be terminated by the Board of Directors on any Exercise Date
if the Board determines that the termination of the Offering Period or the Plan
is in the best interests of the Company and its shareholders. Except as provided
in Section 19 and this Section 20 hereof, no amendment may make any change in
any option theretofore granted which adversely affects the rights of any
participant. To the extent necessary to comply with Section 423 of the Code (or
any successor rule or provision or any other applicable law, regulation or stock
exchange rule), the Company shall obtain shareholder approval in such a manner
and to such a degree as required.

            (b)   Without shareholder consent and without regard to whether any
participant rights may be considered to have been "adversely affected," the
Board (or its committee) shall be entitled to change the Offering Periods, limit
the frequency and/or number of

                                      -8-
<PAGE>

changes in the amount withheld during an Offering Period, establish the exchange
ratio applicable to amounts withheld in a currency other than U.S. dollars,
permit payroll withholding in excess of the amount designated by a participant
in order to adjust for delays or mistakes in the Company's processing of
properly completed withholding elections, establish reasonable waiting and
adjustment periods and/or accounting and crediting procedures to ensure that
amounts applied toward the purchase of Common Stock for each participant
properly correspond with amounts withheld from the participant's Compensation,
and establish such other limitations or procedures as the Board (or its
committee) determines in its sole discretion advisable which are consistent with
the Plan.

            (c)   In the event the Board determines that the ongoing operation
of the Plan may result in unfavorable financial accounting consequences, the
Board may, in its discretion and, to the extent necessary or desirable, modify
or amend the Plan to reduce or eliminate such accounting consequence including,
but not limited to:

                  (i)   altering the Purchase Price for any Offering Period
including an Offering Period underway at the time of the change in Purchase
Price;

                  (ii)  shortening any Offering Period so that Offering Period
ends on a new Exercise Date, including an Offering Period underway at the time
of the Board action; and

                  (iii) allocating shares.

            Such modifications or amendments shall not require stockholder
approval or the consent of any Plan participants.

      21.   Notices. All notices or other communications by a participant to the
Company under or in connection with the Plan shall be deemed to have been duly
given when received in the form specified by the Company at the location, or by
the person, designated by the Company for the receipt thereof.

      22.   Conditions Upon Issuance of Shares. Shares shall not be issued with
respect to an option unless the exercise of such option and the issuance and
delivery of such shares pursuant thereto shall comply with all applicable
provisions of law, domestic or foreign, including, without limitation, the
Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as
amended, the rules and regulations promulgated thereunder, and the requirements
of any stock exchange upon which the shares may then be listed, and shall be
further subject to the approval of counsel for the Company with respect to such
compliance.

            As a condition to the exercise of an option, the Company may require
the person exercising such option to represent and warrant at the time of any
such exercise that the shares are being purchased only for investment and
without any present intention to sell or distribute such shares if, in the
opinion of counsel for the Company, such a representation is required by any of
the aforementioned applicable provisions of law.

      23.   Term of Plan. The Plan shall become effective upon the earlier to
occur of its adoption by the Board of Directors or its approval by the
shareholders of the Company. It shall continue in effect for a term of ten (10)
years unless sooner terminated under Section 20 hereof.

                                      -9-
<PAGE>

      24.   Automatic Transfer to Low Price Offering Period. To the extent
permitted by any applicable laws, regulations, or stock exchange rules, if the
Fair Market Value of the Common Stock on any Enrollment Date within an existing
Offering Period is higher than the Fair Market Value on the Enrollment Date for
the immediately following Offering Period, then all participants in such
existing Offering Period shall be automatically withdrawn from such existing
Offering Period and automatically re-enrolled in the immediately following new
Offering Period as of the first day thereof.

                                      -10-
<PAGE>

                                    EXHIBIT A

                                 E.PIPHANY, INC.

                      EMPLOYEE STOCK PURCHASE PLAN ("ESPP")
                             ENROLLMENT/CHANGE FORM

                      Action                          Complete Sections:
--------------  ---
ACTIONS                  New Enrollment               1,2, 6, 7
--------------  ---
                         Payroll Deduction Change     1, 4, 7
                ---
                         Withdrawal                   1, 5, 7
                ---
                         Beneficiary Change           1, 6, 7
                ---
                         Offering Period Change       1,3,7
                ---
                         Waiver                       1,8
                ---

--------------
SECTION 1:

--------------
EMPLOYEE        Name____________________________________________________________
DATA                  Last                       First                MI

                Home Address____________________________________________________
                                        Street

                ________________________________________________________________
                      City              State             Zip Code

                Social Security #:______________________________________________

--------------
SECTION 2:

--------------
NEW             Effective:                Payroll Deduction Amount:  _____% of
ENROLLMENT      Earnings (Whole percentage up to a maximum of 15%)

                NOTE: You may not accrue the right to purchase more than $25,000
                of stock pursuant to all stock purchase plans of the Company
                during any calendar year.

                [_] May 1, 200__             [_]    November 1, 200__
================================================================================
SECTION 3:
--------------
OFFERING        I recognize that this change ends my participation in any other
PERIOD          Offering as of the date indicated below.  Please withdraw me
CHANGE          from the Offering in which I am currently enrolled and  enroll
                me in the next Offering Period beginning:

                [_] May 1, 200__          [_] November 1, 200__

-------------
SECTION 4:
-------------
PAYROLL         Effective as of _____________________, _____, I authorize the
DEDUCTION       following new level of payroll deduction:  _____% of Earnings
CHANGE          (whole percentage, maximum 15%).
================================================================================
-------------
SECTION 5:
-------------
WITHDRAWAL      Effective with the pay period beginning _____________________, I
                withdraw from the ESPP.

                Your election to withdraw from an Offering cannot be changed,
                and you may not resume participation in the ESPP prior to the
                commencement of the next Offering. In connection with your
                withdrawal, your payroll deductions will be refunded to you as
                soon as practicable.

================================================================================
-------------
SECTION 6:            Beneficiary                    Relationship of Beneficiary

-------------   _____________________________   ________________________________

BENEFICIARY
DESIGNATION

================================================================================
-------------
SECTION 7:
-------------
AUTHORIZATION

I hereby authorize E.piphany, Inc. to enroll me in the ESPP, to make regular
deductions in the amount indicated above, and to purchase shares for me. If I
have elected to withdraw from the ESPP, I authorize E.piphany, Inc. to
distribute my accumulated deductions to me. Any authorization for payroll
deductions will continue until canceled or changed by me in accordance with the
terms of the ESPP. Deductions will cease upon the termination of my status as an
eligible employee or termination of the ESPP or if I have elected to withdraw
from the ESPP. I agree to be bound by the terms and provisions of the ESPP, as
described in the official text of the ESPP, and any applicable offering
document.

      Date:________________________       Signature:____________________________

-------------
SECTION 8:
-------------
WAIVER

I do not wish to participate in E.piphany, Inc.'s Employee Stock Purchase Plan
at this time.

      Date:________________________       Signature:____________________________<PAGE>
                                                                  EXHIBIT 10.7.5

                               FIFTH AMENDMENT TO
                  TECHNOLOGY DEVELOPMENT AND SERVICES AGREEMENT

        This Fifth Amendment to Technology Development and Services Agreement
(the "FIFTH AMENDMENT") is made and entered into as of September 30, 2002, but
shall be effective on July 1, 2002 (the "AMENDMENT EFFECTIVE DATE"), by LYNX
THERAPEUTICS, INC., a Delaware corporation, for itself and its majority-owned
subsidiaries, including SPECTRAGEN, INC., (collectively, "LYNX"), and BAYER
CROPSCIENCE GMBH, a German corporation ("BAYER CropScience"). Lynx and Bayer
CropScience are sometimes referred to herein individually as a "PARTY" and
collectively as the "PARTIES."

                                    RECITALS

A.    The Parties hereto (or their predecessors) previously entered into the
      certain Technology Development and Services Agreement dated October 2,
      1995 as amended by the First Amendment to Technology Development and
      Services Agreement dated September 1, 1997, the Amended and Restated First
      Amendment to Technology Development and Services dated May 1, 1998, the
      Second Amendment to Technology Development and Services Agreement dated
      March 1, 1999 (the "SECOND AMENDMENT"), the Third Amendment to Technology
      Development and Services Agreement dated December 1, 1999, the letter
      agreement dated March 16, 2001, the letter agreement dated November 8,
      2001, the letter agreement dated December 13, 2001, and the Fourth
      Amendment to Technology Development and Services Agreement dated March 31,
      2002 (the "FOURTH AMENDMENT")(collectively, as amended, the "ORIGINAL
      AGREEMENT").

B.    Hoechst Aktiengesellschaft and its subsidiary, Hoechst Marion Roussel,
      Inc. ("HMRI"), were original parties to the Agreement. Hoechst
      Aktiengesellschaft subsequently assigned the Agreement to HMRI and HMRI's
      affiliates. One of HMRI's affiliates, Hoechst Schering AgrEvo GmbH
      ("AgrEvo"), was added as a party to the Original Agreement under the
      Second Amendment. As of December 15, 1999, HMRI and AgrEvo changed their
      names to Aventis Pharmaceuticals, Inc. and Aventis CropScience GmbH,
      respectively. In June 2002, Bayer AG acquired Aventis CropScience GmbH,
      and Aventis CropScience GmbH survived such merger as a wholly owned
      subsidiary of Bayer AG, which subsidiary was renamed Bayer CropScience
      GmbH.

C.    Under Section 5.1 of the Original Agreement, the Original Agreement [*] a
      subscription for Lynx's Analysis services.

D.    The Parties desire to modify the financial terms applicable to Lynx's
      performance of genetic analysis services using the [*] Technology for
      Bayer CropScience, as well as the

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

<PAGE>

      royalties payable by Lynx to Bayer CropScience on the revenues resulting
      from the sale of products or services using or incorporating the [*]
      Technology or the grant of licenses under the [*] Technology to third
      parties.

NOW THEREFORE, in consideration of the foregoing premises and the covenants and
promises contained in this Amendment, the Parties hereby agree that the Original
Agreement shall be amended, effective as of the Amendment Effective Date, as
provided below:

1.  All capitalized terms used but not otherwise defined herein shall have the
    meanings ascribed to such terms in the Original Agreement.

2.  Each reference in the Original Agreement to "Hoechst Schering AgrEvo GmbH"
    and "Aventis CropScience GmbH" shall be replaced by "Bayer CropScience GmbH

3.  Each reference in the Original Agreement to "AgrEvo" and "CropScience" shall
    be replaced by "Bayer CropScience".

4.  Section 2.3 of the Original Agreement as amended shall be amended as
    follows:

    (a) "Aventis CropScience N.V." in the first paragraph is replaced by "Bayer
        BioScience N.V.";

    (b) The first sentence of the second paragraph is amended as follows:

        "In consideration of this license grant, Lynx agrees to pay to Bayer
        CropScience a royalty of [*] of Net Profits received during the first
        [*] years after Product Launch, which royalty shall thereafter be
        decreased to [*] of Net Profits on the [*] of Product Launch, and the
        royalty rate [*] for the remainder of the term of this Agreement."

    (c) "Aventis CropScience N.V." in the fourth paragraph is replaced by "Bayer
        BioScience N.V."

5.  Section 2.4 of the Original Agreement shall be deleted in its entirety.
    Bayer CropScience shall not [*] to Lynx upon Product Launch.

6.  Section 3.9 of the Original Agreement as amended shall be deleted in its
    entirety and replaced with the following:

    "3.9 CREDITS FOR [*] TECHNOLOGY SERVICES. The Parties acknowledge that Bayer
    CropScience or its predecessors-in-interest have made payments to Lynx
    totaling [*] United States Dollars (US [*]) under the Original Agreement,
    which payments are advance payments for the performance by Lynx of genetic
    analyses of biological samples provided by Bayer CropScience or its
    predecessors-in-interest. As of June 30, 2002, Lynx has performed genetic
    analyses using the [*] Technology ("[*] ANALYSES") and other genetic
    analyses of biological samples for Bayer CropScience having a total Value of
    [*] U.S. Dollars, and thus, as of June 30, 2002, Bayer CropScience has a
    remaining credit of [*] U.S. Dollars to be applied against the Value of
    future services under the [*] Development Plan ("[*]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

2 of 4
<PAGE>
    SERVICES") and [*] Analyses to be performed by Lynx ("CREDIT"). On the first
    day of each calendar [*] prior to [*], a flat fee of [*] U.S. Dollars shall
    be charged against the Credit as an advance payment for [*] Services and [*]
    Analyses to be performed by Lynx during such calendar [*]. The Parties
    acknowledge and agree that, regardless of the amount of [*] Services and [*]
    Analyses actually performed by Lynx in such calendar [*], the aggregate
    Value of such [*] Services and [*] Analyses performed in such calendar [*]
    shall be deemed to be [*] U.S. Dollars. If Product Launch does not occur by
    [*], Lynx shall complete the development of the [*] Technology under the [*]
    Development Plan at its sole cost and expense. As of [*], Bayer CropScience
    shall have a remaining Credit in the amount of [*] U.S. Dollars, which
    amount shall be for the performance by Lynx of at least [*] Analyses for
    Bayer CropScience within [*] years after the date of Product Launch. For the
    avoidance of doubt, the Parties hereby expressly agree that Bayer
    CropScience shall never have to pay more than the remaining Credit of [*]
    U.S. Dollars for these [*] Analyses and that in the event the remaining
    Credit of [*] U.S. Dollars is not exhausted after such [*] Analyses, the
    Credit can be further used by Bayer CropScience and its Affiliates for
    additional [*] Analysis. Lynx shall perform [*] Analyses for Bayer
    CropScience and its affiliates on such terms and conditions to be agreed
    upon by the Parties, provided that in no event shall Lynx charge Bayer
    CropScience and its affiliates more than the lesser of (a) the cost charged
    by Lynx to third parties for the performance of similar assays, or (b) [*]
    times Lynx's fully-burdened cost of performing the [*] Analysis."

7.  Section 9 of the Fourth Amendment shall be amended as follows:

    "The term of this Amendment shall be for five (5) years from the first date
    written above and extendable upon mutual agreement and upon extension of the
    Original Agreement. However, even after expiration of this Amendment, at
    first written request of Bayer CropScience, Lynx shall render services with
    respect to the [*] Technology to CropScience and its affiliates under terms
    and conditions to be agreed upon by the Parties, provided that in no event
    shall Lynx charge Bayer CropScience and its affiliates more than the lesser
    of (a) the costs charged by Lynx to third parties for the performance of
    similar assays, or (b) [*] times Lynx' fully-burdened cost of performing the
    [*] Analysis."

8.  Except as amended hereby, the Original Agreement shall remain in full force
    and effect.

9.  This Amendment may be executed in one or more counterparts, each of which
    shall be an original, and all of which shall constitute together the same
    document.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

3 of 4
<PAGE>

IN WITNESS WHEREOF, the parties hereto have duly executed this Amendment as of
the date first written above.

LYNX THERAPEUTICS, INC.                   BAYER CROPSCIENCE GMBH

By:  /s/ Kevin P. Corcoran                By:  /s/ Volkert Sjut
   ----------------------------------        -----------------------------------

Printed Name:  Kevin P. Corcoran          Printed Name:  Volkert Sjut
             ------------------------                  -------------------------

Title:  President and CEO                 Title:  Managing Director
      -------------------------------           --------------------------------

                                          By:  /s/ Gunther Faldie
                                             -----------------------------------
                                          Printed name:  Gunther Faldie
                                                       -------------------------
                                          Title:  General Counsel
                                                --------------------------------

4 of 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00044-of-00352.parquet"}]]